A new non-stimulant ADHD medication that also touches serotonin:
what the evidence actually shows

New ADHD Meds Are Finally Arriving, And This One Works on Serotonin Too

For decades, the ADHD medicine cabinet has looked pretty much the same: stimulants (methylphenidate, amphetamine) plus a small handful of non-stimulants (atomoxetine, guanfacine, clonidine, viloxazine). So any genuinely new mechanism is exciting.

The newest arrival is centanafadine, approved by the FDA in July 2026 under the brand name Simtriyo for adults and children 6 and older. It is described as a first-in-class norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI). Translation: instead of boosting just one or two brain chemicals, it nudges three at once. It is a non-stimulant and is not a controlled substance the way stimulants are.

I'll be honest: the serotonin piece is what caught my attention. Serotonin is central to mood, irritability, and anxiety, and so many people with ADHD are also carrying low mood, rejection sensitivity, or anxiety alongside the attention problems. A single medication that touched both would be genuinely useful.

But excitement is not evidence. Here's what the studies actually show.

First: What Is an "Effect Size," and Why Should You Care?

When researchers say a drug has an "effect size," they're measuring how big the improvement is compared to placebo, in a standardized unit that lets you compare completely different medications on the same ruler.

A rough translation:

• 0.2 = small. Real, but you might not notice it in daily life.
• 0.5 = moderate. Noticeable to you and probably to people around you.
• 0.8 or above = large. The kind of change that visibly alters how your day goes.

This one number is the fairest way to compare a new drug against the old ones, so it's worth learning.

How Well Does Centanafadine Work?

In the two large 6-week adult phase 3 trials, centanafadine did beat placebo, but by a modest margin. On the standard adult ADHD symptom scale, the improvement over placebo was about 3 to 4.5 points, and the effect sizes were 0.24 to 0.40. That is small.

A pooled analysis of five randomized trials (about 1,968 people) found the same thing: an overall effect size of 0.37.

In teenagers (ages 13 to 17), the higher dose beat placebo at 6 weeks, but the lower dose failed to beat placebo at all, an important reminder that the benefit is dose-dependent and not guaranteed.

Now the Head-to-Head Context, Drug by Drug

The most rigorous comparison available is a network meta-analysis of 133 double-blind randomized trials covering more than 18,000 people. Here are the actual clinician-rated effect sizes, by specific drug:

In adults:

• Amphetamines (Adderall, Vyvanse/lisdexamfetamine, Dexedrine, Xelstrym patch): 0.79, large.
• Methylphenidate (Ritalin, Concerta, Focalin, Daytrana): 0.49, moderate.
• Bupropion (Wellbutrin, used off-label): 0.46, moderate.
• Atomoxetine (Strattera): 0.45, moderate.
• Modafinil: not better than placebo in adults.
• Centanafadine: 0.24 to 0.40, small.

In children and adolescents:

• Amphetamines: 1.02, one of the largest treatment effects anywhere in psychiatry.
• Methylphenidate: 0.78.
• Atomoxetine: 0.56.

Amphetamines came out significantly better than methylphenidate, atomoxetine, and guanfacine at the group level, in both children and adults.

Two things worth noticing. First, "non-stimulant" is not one category: atomoxetine at 0.45 in adults is clearly stronger than what centanafadine has shown. Second, when teachers rather than clinicians did the rating in children, only methylphenidate and modafinil separated from placebo, a reminder that who is doing the rating changes the answer.

But Group Averages Hide Individual Differences

Here's a genuinely hopeful finding from crossover studies where the same person tried both stimulants: about 41% responded equally well to amphetamines and methylphenidate, 28% did better on amphetamines, and 16% did better on methylphenidate. Group averages don't predict your result. The only way to know is a careful, monitored trial.

Direct Comparisons Against Centanafadine

No head-to-head trials exist yet, so researchers used statistical matching (a weaker method than randomization) to compare indirectly:

• Versus lisdexamfetamine (Vyvanse): centanafadine produced a 6.6-point smaller improvement in ADHD symptoms.
• Versus extended-release methylphenidate (Concerta): a 4.2-point smaller improvement, though this difference disappeared in one sensitivity analysis.
• Versus atomoxetine and viloxazine (Qelbree): differences were not statistically significant.

An independent review of the entire ADHD drug pipeline put it plainly: nothing currently in development matches the efficacy of stimulants.

So Why Would Anyone Choose It? Tolerability.

This is where it looks genuinely good. In those indirect comparisons, centanafadine had meaningfully lower rates of appetite loss, insomnia, dry mouth, anxiety, jitteriness, and palpitations than lisdexamfetamine and methylphenidate. Most trial side effects were mild or moderate: decreased appetite, nausea, headache, and rash were most common. In adolescents, side effects occurred in about 50% on the higher dose versus 24% on placebo.

That tolerability gap matters, because stimulants are not free. In the same network meta-analysis, amphetamines were less well tolerated than placebo in both children and adults; guanfacine was worse than placebo in children; and atomoxetine, methylphenidate, and modafinil were worse than placebo in adults. Real people stop medications over exactly these problems.

There were also encouraging secondary findings for centanafadine in children and adolescents: improvements in executive functioning and learning problems, not just core symptoms, visible as early as week 1.

About That Serotonin Hope: A Reality Check

Centanafadine does block the serotonin transporter. But the trials measured ADHD symptoms, not depression or mood outcomes. There is currently no trial evidence that its serotonin activity delivers an antidepressant or mood benefit on top of ADHD control.

It's also worth knowing this isn't unprecedented: viloxazine (Qelbree) is already described as a serotonin-norepinephrine modulator, and it did not turn out to be a mood drug either. Serotonin activity on paper does not automatically become mood improvement in a patient. Treat it as a plausible idea, not a proven one.

A Safety Note on the Non-Stimulants

Both atomoxetine and viloxazine carry a boxed warning for suicidal thoughts and behavior, particularly early in treatment and after dose changes. Anyone starting a non-stimulant should have a plan for who to call if mood worsens.

Questions Worth Bringing to Your Prescriber

• Is my main problem efficacy (nothing is working well enough) or tolerability (it works but I can't live with the side effects)? The answer points to different drugs.
• Have I actually tried both classes of stimulant? Roughly a quarter of people do meaningfully better on one than the other.
• Is this medication covered by my insurance, and what does it cost out of pocket? Brand-new drugs often have limited coverage in their first year.
• What are we measuring, and when will we decide whether it worked? Six weeks is the standard trial length in the research.

The Honest Bottom Line

A new mechanism is real progress, especially for people who can't tolerate stimulants, who have a history of substance use, or who dread the appetite crash and the 3 a.m. wakeups. But centanafadine should be understood as a gentler option, not a stronger one. Its effect size is roughly a third to a half that of amphetamines.

If stimulants work well and are tolerated, the evidence still favors staying with them. But more than a third of children and half of adults stop ADHD medication within the first year, usually because of side effects or inadequate response, and for those people, another well-tolerated option on the shelf genuinely matters.

This post is for education and is not a substitute for medical advice.